Overview

Atomoxetine and Huntington's Disease

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements in subjects with early Huntington Disease (HD) and attention deficit disorder (ADD).
Phase:
Phase 2
Details
Lead Sponsor:
University of Iowa
Collaborator:
Eli Lilly and Company
Treatments:
Atomoxetine Hydrochloride